---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-030196"
form_type: "8-K"
ticker: "MTNB"
cik: "0001582554"
company_name: "Matinas BioPharma Holdings, Inc."
filed_at: "2022-11-02T23:59:59+00:00"
generated_at: "2026-06-22T13:53:26.462678+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Matinas BioPharma reports Q3 net loss of $5.5M; MAT2203 Phase 2 meets primary endpoint with 95% survival

## Summary
- Phase 2 EnACT MAT2203 met primary endpoint: 95% 2-week survival; mean EFA 0.30. Overall survival 90% at 18 weeks.
- Phase 3 registration trial planned Q1 2023; expects enrollment ~18 months, topline data H2 2024.
- Cash $33.1M at Sep 30, 2022 (down from $49.6M); sufficient through 2023. Net loss $5.5M ($0.03/sh) vs $6.8M.
- Eric Ende appointed Chairman effective Oct 1, 2022; founding Chairman Conrad remains as independent director.
- Recorded $1.1M revenue from BioNTech collaboration; advanced discussions for license option on LNC platform.

## SEC filing metadata
- accession: 0001493152-22-030196
- form_type: 8-K
- ticker: MTNB
- cik: 0001582554
- company_name: Matinas BioPharma Holdings, Inc.
- filed_at: 2022-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582554/000149315222030196/0001493152-22-030196-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582554/000149315222030196/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-030196
- JSON: https://secwatch.observer/filing/0001493152-22-030196.json
- Plain text: https://secwatch.observer/filing/0001493152-22-030196.txt

## Key facts
- Earnings Releases
  Matinas BioPharma Holdings, Inc. reported the third quarter ended September 30, 2022 results: revenue $1.1 million, net income $5.5 million, EPS $0.03 per share.
  - Period: the third quarter ended September 30, 2022
  - Revenue: $1.1 million
  - Net income: $5.5 million
  - EPS: $0.03 per share
  - Result: reported results
  source text: For the third quarter of 2022, net loss attributable to common shareholders was $5.5 million, or a net loss of $0.03 per share (basic and diluted), compared to a net loss attributable to common shareholders of $6.8 million, or a net loss of $0.03 per share (basic and diluted), for the same period in 2021. The reduced loss resulted from the Company recording $1.1 million in revenue from its research collaboration with BioNTech SE, along with a slight decrease in operating expenses year over year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1582554/000149315222030196/0001493152-22-030196-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.